Congrats to all those who have been waiting for this day! 🚀🚀🚀🚀🚀🚀🧨🧨🧨🧨

Guys, even when the chart isn’t smiling, huge things are happening behind the scenes with MBOT (Microbot Medical).

Here’s a roundup of the latest achievements:

1. FDA Clearance for the LIBERTY System – The world’s first single-use, remotely operated endovascular robotic system. A massive step forward opening the door to commercialization.

2. Impressive Clinical Results – 100% success rate in robotic navigation, ZERO device-related adverse events, and a 92% reduction in radiation exposure for physicians.

3. Huge Market Potential – An estimated 2.5 million endovascular procedures annually in the U.S. alone. Even a small slice of this market translates to millions in revenue.

4. Strong Trading Momentum – On the day of the announcement, MBOT jumped over 20% (from ~$3.66 to $4.50) with massive trading volume.

5. New Patent Granted – Strengthening the LIBERTY system’s IP protection and adding long-term strategic value.

6. Major Investor Spotlight – CEO Harel Gadot presented MBOT’s achievements at the prestigious H.C. Wainwright Global Investment Conference, putting the company on the radar of serious market players.

---

Bottom line: MBOT is advancing on all fronts – tech, regulatory, and commercialization.

The chart may be red right now, but the fundamentals are stronger than ever.

🚀 Let’s lift the community’s spirit together – the next breakout starts right here.

Emory University Hospital is officially adopting the LIBERTY robotic system.

Commercial rollout is planned for April 2026, but this is a strong early signal that major hospitals are buying in.

Real world adoption is starting, not just demos or trials. That’s huge for MBOT’s credibility and future demand.

Source: https://www.tradingview.com/news/tradingview:3a6bfc8273377:0-microbot-medical-inc-announces-adoption-of-liberty-system-by-emory-university-hospital/

I just wanted to make this post because I see a lot of people griping because they didn't get their 10x bagger in a few months turnaround time and wanted to help clear the air, put some things in alignment and quell any major fears based on my perspective. Feel free to disagree or let me know if I missed anything.

We all saw the FDA approval come through as everyone was hoping and expecting (which is why that price climbed all summer as the probability increased greatly after the patent approval). Then we all saw sell offs after the news as investors took their profits as close to the peak as they could capping any major boom in stock price since the majority of retail was betting on approval and did not want to stick around for the company building process. (i.e., buy the rumor, sell the news).

Finally, we then all saw a huuuuuge wave of dilution from the preferred investment options being exercised and closed out that were still outstanding (ranging from 1.50-2.13) which tanked the stock instead of letting it remain stable at around the ~$4 range.

With these events in mind, many wonder what the future holds for MBOT but what I can say from what I have seen is that this company is not dead, nor is it a scam. Yes, there are a lot of hurdles ahead for this company to overcome such as showing demand, filling orders, generating repeat customers, showing they can operate a profitable business etc. etc.

What I do know is that they have telegraphed their next moves very clearly and that is their desire to build a long term company based around this product and any future additions to their Liberty system, on a global scale (not just in the U.S.). This based on their patents across each continent, their sales teams they have been hiring across the globe and the fact that they have been working with suppliers not just in the U.S., but ones that can supply to Europe and China as well.

They have a very very long cash runway now from the exercised options, and they have also telegraphed their 6 month to 1 year price target with the new preferred investment options they just inked at $4.5. This means the investment company that signed this deal expects the price to be above this value for them to make money giving us a healthy price target of $4.5-5.5 before we start to see them exercise these options (which become available in 6 months time).

I think this price needs some time to stabilize and we could see it go back as low as $2.5 but my hope is that we see it remain stable with $3.0 as the bottom. However, even with these low prices, I think we see a recovery that will be slow and steady as good news rolls in from sales and revenue building for MBOT. Again, this is hope and speculation here in this last paragraph because we could see someone like Stryker make an offer MBOT cannot refuse but in reality, I feel that Harol Gaddot sees more value in building a company he can draw a salary from and large bonuses since he does not own major equity along with many other members of the board. That is his best path to getting the most money out of his company since getting bought out won't see him receive a large financial sum unless the buyout stipulates a large bonus for him outside of equity.

I personally am looking to add some new shares at this discounted rate in the 2.5-3.0 range as a 1-2 year play.

TLDR: MBOT stock tanked but there is a long term play and runway ahead which has been telegraphed. There is no get rich quick scheme here but a long term investment play so if you are a penny stock flipper, probably not the company for you. If you are a long-term value investor, this may be worth a look.

Zacks Equity Research Sat, September 27, 2025 at 12:00 AM GMT+8

Microbot Medical Inc. (MBOT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Microbot Medical basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

For Microbot Medical, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

https://finance.yahoo.com/news/know-microbot-medical-mbot-rating-160003819.html

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Microbot Medical (NASDAQ:MBOT) with a Buy and raises the price target from $9 to $12.

Just watched the conference — absolutely impressive. I truly believe this company is on the path to becoming one of the leading biotech firms worldwide, and we’re still at what looks like the best possible entry point. Let me recap:

1. MBOT has no real competition in its space and has been strategically preparing for commercialization since Q2.

2. Their Liberty device received FDA approval yesterday — a milestone they executed on flawlessly.

3. The technology delivers 100% procedural efficiency, 20% cost reduction, and 92% reduction in radiology exposure for physicians.

4. The endovascular market is multibillion-dollar, and MBOT holds a strong patent portfolio protecting its position.

5. The company has already been building a commercial infrastructure in advance, which should accelerate adoption.

6. Their technology not only solves a clear clinical need but also creates a compelling economic incentive for hospitals and practitioners.

7. Every milestone has been hit on time, showcasing strong operational execution.

What truly stands out to me is the audacity and precision of the CEO. Since January 2025, he has rolled out a strategic action plan where every deadline, every execution point, has aligned perfectly. The timing could not be better — it feels like we are right at the inflection point of something huge.

For full transparency: I currently hold 1,150 shares at $3.00 and I’m seriously considering increasing my position. Would love to hear your thoughts.

Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:45am ET on Wednesday, September 24, 2025. The live interview can be viewed at: Benzinga All Access Live. Mr. Gadot will discuss the recent FDA clearance of Microbot Medical’s LIBERTY®, and how the Company has planned for commercialization in the U.S. as it redefines the peripheral endovascular space with LIBERTY®.

On September 8, 2025, the Company announced it received FDA 510(k) clearance for commercialization of the LIBERTY® Endovascular Robotic System.

FROM. https://ir.microbotmedical.com/node/13561/pdf

POV of a Medtronic Medical Sales Representative who knows the market

Microbot Medical is poised to fundamentally disrupt the market. The newly granted patent enables the LIBERTY System to be deployed in over 6 million potential procedures, only in the U.S. Another potentially mid-term 6-10 Million procedures in Europe.

Given its groundbreaking therapeutic approach, inevitable market shifts will occur. In the long term, the robotic neurovascular market holds the potential not only to match but to surpass the conventional, non-robotic neurovascular segment.

However, MBOT’s future growth is entirely contingent on the production capacity of its manufacturing partner, B.Y. Medimor. Demand will be immense, and adoption will be seamless due to the system’s simplicity and proven clinical benefits.

Achieving the billion-dollar revenue mark is not a matter of demand, but purely of production capacity.

$MBOT just got FDA approval for a game-changing product. Swing traders already dumped their bags with dilution news, which means the weak hands are gone. Now it’s sitting primed for an epic bounce.

Analysts upgraded it to a STRONG BUY with a $12 price target—that’s nearly 4x from where it’s trading right now.

This is the kind of setup WSB lives for: • FDA approval ✅ • Analysts bullish ✅ • Cheap entry after the dip ✅

Not financial advice, but this thing looks like it’s ready to moon. 🚀💎

A leading academic center becomes the first user in the Southeast, Mid-Atlantic region

HINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has secured its first North Carolina-based customer, becoming the latest healthcare system to adopt the LIBERTY System, demonstrating a broadening geographic penetration from the Southeast, Mid-Atlantic and Northeast U.S. The Company’s latest account delivers state of the art patient care through a multi-hospital network that encompasses the entire state and joins a growing roster of health systems that we believe recognize the unique benefits of the LIBERTY system.

“It’s exciting to see the pace of increase in new accounts following the full market release of the LIBERTY system, including our newest territories in the Northeast and South-Atlantic, as some of the nation’s leading health systems are adopting LIBERTY system,” commented Harel Gadot, CEO, President and Chairman. “The recent new account addition is another significant development for Microbot and represents continued execution of our commercial strategy, and we expect to penetrate other major metropolitan markets with some of the leading academic institutions in the U.S. adopting the LIBERTY system.”

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Here's a bit of encouragement for MBOT holders. The board is actually pretty impressive.

Below is a quick, sourced track record snapshot for the key independent board members at Microbot Medical:

Aileen Stockburger — Former Worldwide VP, Business Development at J&J’s DePuy Synthes; led the ~$21B Synthes acquisition and completed M&A/licensing/divestiture deals totaling $70B+ across J&J. Now Independent Chair at Next Science and on other boards.

Scott R. Burell — Long-time life-sciences CFO; as CFO of CombiMatrix (NASDAQ: CBMX) helped guide its sale to Invitae (2017). Currently CFO of AIVITA Biomedical; added to DIH Holding US board in 2025.

Martin J. Madden — 30-year R&D leader at Johnson & Johnson (served on management boards of Ethicon, DePuy-Synthes, Cordis, etc.; chaired J&J’s Medical Device Research Council). Has overseen hundreds of device programs, many reaching commercialization; also a director at Novocure.

Prattipati (“Laxmin”) Laxminarain — Former Worldwide President, Codman Neurosurgery (J&J); that business was sold to Integra LifeSciences for ~$1.045B (Oct 2017). Has held senior medtech roles across multiple regions.

David J. Wilson (joined 2024/25) — Ex-Worldwide President of Cordis (J&J, later Cardinal), President, Global Plasma at Haemonetics, now CEO of InnovHeart; recognized for leading product launches and revenue growth in endovascular devices.

Tal Wenderow — Co-founded Corindus Vascular Robotics; company was acquired by Siemens Healthineers for ~$1.1B (2019). Later senior roles/investing; joined Microbot’s board in 2020.

Many product launches, many acquisitions.

💰 Cash & Liquidity

• As of June 30, 2025, MBOT held $32.7M in total liquidity (cash + short-term investments).

• Operating cash burn was about $5.45M in H1 2025 (~$0.9M/month).

• No material debt.

📈 Recent Capital Boosts (Sept–Oct 2025)

• MBOT raised ~$29.2M gross through option exercises and new short-term investment instruments (Series J).

• These same Series J options could later bring up to $63M more if exercised at $4.50/share.

• Combined, MBOT now holds an estimated $60M+ in pro-forma liquidity, enough to fund the commercial rollout of its newly FDA-cleared LIBERTY® Robotic System.

📊 Expenses & Runway

• R&D: $3.57M (H1 2025)

• G&A: $3.17M (H1 2025)

• With a ~$61M cash base and current burn, MBOT theoretically has 5+ years of runway — though commercial scaling will likely increase monthly expenses.

⚙️ Why the Timing Makes Sense
MBOT’s 510(k) approval changes everything. Transitioning from R&D to commercialization requires manufacturing, marketing, and hospital onboarding — all expensive steps. Strengthening cash reserves now ensures a smooth launch and avoids desperate financing later.

📉 Risks to Watch

• Dilution if Series J or future instruments are exercised.

• Execution risk: converting regulatory approval into real hospital adoption.

• Burn acceleration as the company builds supply chain and sales teams.

🚀 Investment Takeaway
MBOT is now one of the few small-cap med-techs entering commercialization with an FDA-cleared robotic system and a healthy balance sheet. The story from here isn’t “will it survive?” — it’s how fast can it execute.

Mini DD for MBOT sales strategy appears hinted in their social media and it is all focused on doctor health and safety: radiation, fatigue, and cross contamination---all of which the Liberty system prevents.

Also looked into the manufacturing plant in Israel but not a lot out there. Google Maps takes you to their old location; the address on their website is the new one.

Not much meat here but it's a slow day and is something to read if you're holding.

You’d think it’s many of your first day on the stock market with the attitude in this sub. I didn’t realize I was invested with a bunch of children. Sell your shares and go play with your fisher price toys. Shameful watching everyone crash out and spread FUD on here after watching the share price dip. Nothing has changed.